TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03606187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimgenics SCS Programming Approach
Description: Stimgenics SCS Programming approach Using Intellis(TM) SCS system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard SCS Programming Approach
Description: Standard SCS Programming approach using Intellis(TM) SCS system
Study: NCT00394550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supraglottoplasty with laser
Description: Polysomnogram, fiberoptic flexible laryngoscopy, adenotonsillectomy, direct laryngoscopy, bronchoscopy, laser supraglottoplasty, general anesthesia, a proton-pump inhibitor ibuprofen, acetaminophen with codeine without alcohol, or other narcotic containing medication, antibiotic, possible use of other analgesics per anesthesia None of these procedures are new or experimental. Our investigation pertains to a broader use of the laser supraglottoplasty to include children with obstructive sleep apnea and laryngomalacia, as opposed to the more traditional use of laser supraglottoplasty for only severe laryngomalacia in young children

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supraglottoplasty with laser
Description: laser excision of laryngomalacia (floppy tissue) on one side of the supraglottis
Study: NCT03450954

Intervention type: PROCEDURE
Intervention: Amniotic membrane transplant
Description: Amniotic membrane graft was transplanted onto the bullous cornea by the inlay technique
Study: NCT03441061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV
Study: NCT02265250

Intervention type: OTHER
Intervention: MRI
Description: Noncontrast T1- and T2-weighted 3.0 T MRI of the bilateral carotid, coronary, and superficial femoral arteries

Intervention type: OTHER
Intervention: MRI
Description: Noncontrast T1- and T2-weighted 3.0 T MRI of the bilateral carotid, coronary, and superficial femoral arteries

Intervention type: OTHER
Intervention: MRI
Description: Noncontrast T1- and T2-weighted 3.0 T MRI of the bilateral carotid, coronary, and superficial femoral arteries

Intervention type: OTHER
Intervention: MRI
Description: Noncontrast T1- and T2-weighted 3.0 T MRI of the bilateral carotid, coronary, and superficial femoral arteries

Intervention type: OTHER
Intervention: PET/MRI
Description: Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries

Intervention type: OTHER
Intervention: PET/MRI
Description: Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries

Intervention type: OTHER
Intervention: PET/MRI
Description: Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries

Intervention type: OTHER
Intervention: Laboratory blood test
Description: Cardiovascular biomarkers

Intervention type: OTHER
Intervention: Laboratory blood test
Description: Cardiovascular biomarkers

Intervention type: OTHER
Intervention: Laboratory blood test
Description: Cardiovascular biomarkers

Intervention type: OTHER
Intervention: Laboratory blood test
Description: Cardiovascular biomarkers
Study: NCT01647893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTB-001
Description: IV bolus or IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTB-001
Description: IV bolus or IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTB-001
Description: IV bolus or IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTB-001
Description: IV bolus or IV infusion
Study: NCT04343755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
Study: NCT00838240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study: NCT00135226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Omega-3 Ethyl Esters
Study: NCT00838240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study: NCT01456169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan medoxomil/placebo
Description: Azilsartan medoxomil and placebo to chlorthalidone combination tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil - chlorthalidone
Description: Azilsartan medoxomil and chlorthalidone fixed dose combination tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil - chlorthalidone
Description: Azilsartan medoxomil and chlorthalidone fixed dose combination tablets
Study: NCT01011140

Intervention type: BEHAVIORAL
Intervention: Survey
Description: 10-15 minute online survey to assess palliative care physicians' attitudes, beliefs and practice patterns related to parenteral hydration at the end of life in Latin America and Spain.
Study: NCT05356780

Intervention type: DEVICE
Intervention: Aligner
Description: A method of straightening teeth without fixed braces

Intervention type: DEVICE
Intervention: Aligner
Description: A method of straightening teeth without fixed braces
Study: NCT02292446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: supplied as 5 mg, 10 mg and 20 mg tablets to be taken orally
Study: NCT01687101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STOPAIN topical gel
Description: STOPAIN topical gel is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
Study: NCT04656457

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Description: Treadmill is not used to harness power, but as exercise machines for running or walking in one place. Rather than the user powering the mill, the machine provides a moving platform with a wide conveyor belt driven by an electric motor or a flywheel. The belt moves to the rear, requiring the user to walk or run at a speed matching that of the belt. The rate at which the belt moves is the rate of walking or running. Thus, the speed of running may be controlled and measured

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resisted exercises
Description: Resistance exercises will be involved in this technique are for upper and lower limb (Exercise program including shoulder flexion, abduction and horizontal adduction, elbow extension and flexion, calf raise, leg extension and squatting)
Study: NCT01112787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Foam
Description: Tazarotene Foam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Laural Sulfate
Description: Sodium Laural Sulfate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled Water
Description: Distilled Water
Study: NCT05899400

Intervention type: DIAGNOSTIC_TEST
Intervention: Diascopic iON Image Analysis System
Description: A scanning digital optical train that images sputum slides for automated analysis by a tuberculosis detecting algorithm
Study: NCT00392730

Intervention type: DIETARY_SUPPLEMENT
Intervention: Remove Mn from PN if evidence of increased brain Mn on MRI
Description: Withhold Mn-containing trace element cocktail and add zinc, copper and chromium individually to PN

Intervention type: DIETARY_SUPPLEMENT
Intervention: Remove Mn from PN if evidence of increased brain Mn on MRI
Description: Withhold Mn-containing trace element cocktail and add zinc, copper and chromium individually to PN

Intervention type: DIETARY_SUPPLEMENT
Intervention: Remove Mn from PN if evidence of increased brain Mn on MRI
Description: Withhold Mn-containing trace element cocktail and add zinc, copper and chromium individually to PN
Study: NCT02553395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phenacite (Test) contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A contact lens
Study: NCT04270799

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Classification
Description: Patient's scans will be used as input into in-house software to extract multiple radiomics features. These features will be used to develop a risk-signature which can predict malignancy risk. Patient scans will also be used as input into deep learning/convolutional neural network models to perform automated imaging classification.
Study: NCT03619772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral
Description: Participants will control game using EMG from both upper limbs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral
Description: Participants will control game using EMG from the more impaired upper limb.
Study: NCT04086095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neofact application aid
Description: The Neofact application aid is a specifically for the LISA procedure designed guide of a soft catheter and replaces the Magill forceps. Catheter (3.5 Fr.) and guide are already combined and packed together sterile. The catheter tip is marked in black (1cm).
Study: NCT04991675

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor muscle exercises
Description: During the first visit, the anatomy of the pelvic floor and the purpose of the program were explained. Exercises were taught in the supine position, as described by Kegel (1948), it was confirmed that the women learned to use the correct muscles with vaginal palpation. During the exercise, the participants were informed not to pull the abdomen inwards, not to tighten their legs and hip muscles, and not move their pelvis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diaphragmatic breathing exercises
Description: During the first visit, the anatomy of the diaphragm and abdominal wall and the purpose of the program were explained. Diaphragmatic breathing exercise was taught in supine position. The movement of the symphysis pubis was examined to confirm that the pelvic floors' movement was also involved breathing. Abdominal palpation was used to elicit unawareness of the diaphragmatic breathing and to assess whether contractions were performed correctly.
Study: NCT03205683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraneural facilitation (INF)
Description: INF is a novel non-invasive therapy based on the principle of restoring vascular function at the capillary level in peripheral nerve.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham INF
Description: Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm.
Study: NCT02384733

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Loco-regional RT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Loco-regional RT
Study: NCT00823667

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Palliative care intervention at weeks 3,4,5 and 6 post study enrollment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical chart review
Description: Occurs at 1 year post study enrollment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical chart review
Description: Occurs at 1 year post study enrollment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: end-of-life treatment/management
Description: Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: end-of-life treatment/management
Description: Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care
Description: Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
Study: NCT02222649

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: High dose of 200,000 IU of cholecalciferol orally in a single dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules of starch, no therapeutic action
Study: NCT03726502

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ureteroscopy with safety guide-wire
Description: ureteroscopy with use of safety guide-wire in treatment of ureteral stone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ureteroscopy with safety guide-wire
Description: ureteroscopy with use of safety guide-wire in treatment of ureteral stone

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ureteroscopy alone
Description: ureteroscopy without use of safety guide-wire in treatment of ureteral stone

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ureteroscopy alone
Description: ureteroscopy without use of safety guide-wire in treatment of ureteral stone

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: without safety guide-wire
Description: ureteroscopy without use of safety guide-wire in treatment of ureteral stone

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: without safety guide-wire
Description: ureteroscopy without use of safety guide-wire in treatment of ureteral stone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: with safety guide-wire
Description: ureteroscopy with use of safety guide-wire in treatment of ureteral stone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: with safety guide-wire
Description: ureteroscopy with use of safety guide-wire in treatment of ureteral stone
Study: NCT01739738

Intervention type: DEVICE
Intervention: Ureteral Stent
Description: patients who need to receive stent as per standard of care
Study: NCT03031782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab
Description: secukinumab is a high-affinity fully human monoclonal anti-human antibody that targets IL-17A and neutralizes activity.
Study: NCT02477072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACT
Description: Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACT
Description: Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
Study: NCT00262028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-PS Vaccine
Study: NCT02711202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MabCampath,
Description: Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MabCampath,
Description: Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
Study: NCT03031782

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matched placebo to AIN457 for use in the double blind Treatment Period 2
Study: NCT01941706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project UPLIFT
Description: Developed for home-based treatment of depression in people with epilepsy, Project UPLIFT is based upon Mindfulness-based Cognitive Therapy for depression. It includes 8 modules, group-delivered by either telephone or Web. Trainees and people with epilepsy co-facilitate the groups, supervised by a licensed mental health professional.The co-facilitators are trained and supervised by the Principal Investigator, a Georgia-licensed clinical psychologist and Associate Professor of Behavioral Science and of Epidemiology in public health. Activities are designed to increase knowledge about depression; monitoring, challenging, and changing thoughts; coping and relaxing; attention and mindfulness; focusing on pleasure; the importance of reinforcement, and preventing relapse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project UPLIFT
Description: Developed for home-based treatment of depression in people with epilepsy, Project UPLIFT is based upon Mindfulness-based Cognitive Therapy for depression. It includes 8 modules, group-delivered by either telephone or Web. Trainees and people with epilepsy co-facilitate the groups, supervised by a licensed mental health professional.The co-facilitators are trained and supervised by the Principal Investigator, a Georgia-licensed clinical psychologist and Associate Professor of Behavioral Science and of Epidemiology in public health. Activities are designed to increase knowledge about depression; monitoring, challenging, and changing thoughts; coping and relaxing; attention and mindfulness; focusing on pleasure; the importance of reinforcement, and preventing relapse.
Study: NCT01373723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different alternatives to improve the coverage of the populational screening programmes of cervical cancer
Description: Cost-effectiveness analysis of 3 strategies to increase the recruitment of population screening for cervical cancer. These interventions will be compared to the current opportunistic screening strategy
Study: NCT02711202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remicade
Description: Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remicade
Description: Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
Study: NCT00823667

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care
Description: Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
Study: NCT02968342

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal progesterone 8%
Description: vaginal self application

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone 8%
Description: vaginal self application
Study: NCT03040674

Intervention type: PROCEDURE
Intervention: Cell therapy
Description: Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day
Study: NCT01373723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different alternatives to improve the coverage of the populational screening programmes of cervical cancer
Description: Cost-effectiveness analysis of 3 strategies to increase the recruitment of population screening for cervical cancer. These interventions will be compared to the current opportunistic screening strategy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different alternatives to improve the coverage of the populational screening programmes of cervical cancer
Description: Cost-effectiveness analysis of 3 strategies to increase the recruitment of population screening for cervical cancer. These interventions will be compared to the current opportunistic screening strategy
Study: NCT00036634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir DF
Description: Tenofovir DF tablet administered orally once daily
Study: NCT01755130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photoacoustic Imaging
Description: Undergo LOUISA 3D
Study: NCT02477072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEG
Description: Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
Study: NCT01479842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTK inhibitor PCI-32765
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01803828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: 20 mg/die (1 capsule)